Literature DB >> 29662218

Tapping the RNA world for therapeutics.

Judy Lieberman1.   

Abstract

A recent revolution in RNA biology has led to the identification of new RNA classes with unanticipated functions, new types of RNA modifications, an unexpected multiplicity of alternative transcripts and widespread transcription of extragenic regions. This development in basic RNA biology has spawned a corresponding revolution in RNA-based strategies to generate new types of therapeutics. Here, I review RNA-based drug design and discuss barriers to broader applications and possible ways to overcome them. Because they target nucleic acids rather than proteins, RNA-based drugs promise to greatly extend the domain of 'druggable' targets beyond what can be achieved with small molecules and biologics.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29662218      PMCID: PMC6052442          DOI: 10.1038/s41594-018-0054-4

Source DB:  PubMed          Journal:  Nat Struct Mol Biol        ISSN: 1545-9985            Impact factor:   15.369


  127 in total

1.  Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication.

Authors:  Miguel A Martínez; Arantxa Gutiérrez; Mercedes Armand-Ugón; Julià Blanco; Mariona Parera; Jordi Gómez; Bonaventura Clotet; José A Esté
Journal:  AIDS       Date:  2002-12-06       Impact factor: 4.177

2.  mRNA: Fulfilling the Promise of Gene Therapy.

Authors:  Drew Weissman; Katalin Karikó
Journal:  Mol Ther       Date:  2015-09       Impact factor: 11.454

3.  An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria.

Authors:  Abigail Liebow; Xingsheng Li; Timothy Racie; Julia Hettinger; Brian R Bettencourt; Nader Najafian; Patrick Haslett; Kevin Fitzgerald; Ross P Holmes; David Erbe; William Querbes; John Knight
Journal:  J Am Soc Nephrol       Date:  2016-07-18       Impact factor: 10.121

4.  Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability.

Authors:  Katalin Karikó; Hiromi Muramatsu; Frank A Welsh; János Ludwig; Hiroki Kato; Shizuo Akira; Drew Weissman
Journal:  Mol Ther       Date:  2008-09-16       Impact factor: 11.454

5.  Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy.

Authors:  Merrill D Benson; Noel R Dasgupta; Stacy M Rissing; Jessica Smith; Harvey Feigenbaum
Journal:  Amyloid       Date:  2017-09-14       Impact factor: 7.141

6.  Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

Authors:  Shannon L Maude; Theodore W Laetsch; Jochen Buechner; Susana Rives; Michael Boyer; Henrique Bittencourt; Peter Bader; Michael R Verneris; Heather E Stefanski; Gary D Myers; Muna Qayed; Barbara De Moerloose; Hidefumi Hiramatsu; Krysta Schlis; Kara L Davis; Paul L Martin; Eneida R Nemecek; Gregory A Yanik; Christina Peters; Andre Baruchel; Nicolas Boissel; Francoise Mechinaud; Adriana Balduzzi; Joerg Krueger; Carl H June; Bruce L Levine; Patricia Wood; Tetiana Taran; Mimi Leung; Karen T Mueller; Yiyun Zhang; Kapildeb Sen; David Lebwohl; Michael A Pulsipher; Stephan A Grupp
Journal:  N Engl J Med       Date:  2018-02-01       Impact factor: 91.245

7.  A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.

Authors:  Kevin Fitzgerald; Suellen White; Anna Borodovsky; Brian R Bettencourt; Andrew Strahs; Valerie Clausen; Peter Wijngaard; Jay D Horton; Jorg Taubel; Ashley Brooks; Chamikara Fernando; Robert S Kauffman; David Kallend; Akshay Vaishnaw; Amy Simon
Journal:  N Engl J Med       Date:  2016-11-13       Impact factor: 91.245

Review 8.  Identifying druggable disease-modifying gene products.

Authors:  Scott J Dixon; Brent R Stockwell
Journal:  Curr Opin Chem Biol       Date:  2009-09-07       Impact factor: 8.822

Review 9.  CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes.

Authors:  Alexis C Komor; Ahmed H Badran; David R Liu
Journal:  Cell       Date:  2016-11-17       Impact factor: 41.582

10.  Modulation of HIV-1 replication by RNA interference.

Authors:  Jean-Marc Jacque; Karine Triques; Mario Stevenson
Journal:  Nature       Date:  2002-06-26       Impact factor: 69.504

View more
  57 in total

Review 1.  Programmable RNA manipulation in living cells.

Authors:  Yu Pei; Mingxing Lu
Journal:  Cell Mol Life Sci       Date:  2019-07-31       Impact factor: 9.261

2.  Long Noncoding RNA Signatures Induced by Toll-Like Receptor 7 and Type I Interferon Signaling in Activated Human Plasmacytoid Dendritic Cells.

Authors:  Rochelle C Joslyn; Adriana Forero; Richard Green; Stephen E Parker; Ram Savan
Journal:  J Interferon Cytokine Res       Date:  2018-09       Impact factor: 2.607

3.  Pharmacological PTEN inhibition: potential clinical applications and effects in tissue regeneration.

Authors:  Gabriel A Borges; Liana P Webber; Ana Elizia M Marques; Eliete Ns Guerra; Rogerio M Castilho; Cristiane H Squarize
Journal:  Regen Med       Date:  2020-03-30       Impact factor: 3.806

4.  Emerging roles of novel small non-coding regulatory RNAs in immunity and cancer.

Authors:  Domenico Rosace; Judith López; Sandra Blanco
Journal:  RNA Biol       Date:  2020-03-18       Impact factor: 4.652

Review 5.  The Landscape of Early Clinical Gene Therapies outside of Oncology.

Authors:  Laure Rittié; Takis Athanasopoulos; Miguel Calero-Garcia; Marie L Davies; David J Dow; Steven J Howe; Alastair Morrison; Ida Ricciardelli; Aurore Saudemont; Laurent Jespers; Timothy M Clay
Journal:  Mol Ther       Date:  2019-09-06       Impact factor: 11.454

6.  Myeloid cell-targeted miR-146a mimic inhibits NF-κB-driven inflammation and leukemia progression in vivo.

Authors:  Yu-Lin Su; Xiuli Wang; Mati Mann; Tomasz P Adamus; Dongfang Wang; Dayson F Moreira; Zhuoran Zhang; Ching Ouyang; Xin He; Bin Zhang; Piotr M Swiderski; Stephen J Forman; David Baltimore; Ling Li; Guido Marcucci; Mark P Boldin; Marcin Kortylewski
Journal:  Blood       Date:  2020-01-16       Impact factor: 22.113

Review 7.  Let-7 microRNA as a potential therapeutic target with implications for immunotherapy.

Authors:  Maud-Emmanuelle Gilles; Frank J Slack
Journal:  Expert Opin Ther Targets       Date:  2018-10-17       Impact factor: 6.902

Review 8.  More than a messenger: Alternative splicing as a therapeutic target.

Authors:  A J Black; J R Gamarra; J Giudice
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2019-07-02       Impact factor: 4.490

9.  RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges.

Authors:  Ai-Ming Yu; Young Hee Choi; Mei-Juan Tu
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

10.  Amide-Modified RNA: Using Protein Backbone to Modulate Function of Short Interfering RNAs.

Authors:  Venubabu Kotikam; Eriks Rozners
Journal:  Acc Chem Res       Date:  2020-07-13       Impact factor: 22.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.